This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

June 27, 2025

Company name: Modalis Therapeutics Corporation
Stock exchange listing: Tokyo Stock Exchange
Code number: 4883
URL: https://www.modalistx.com/en/
Representative: Haruhiko Morita

Notice of Outlook for IND Filing of MDL-101

27-June-2025 TOKYO & Waltham, Mass – Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative products for the treatment of rare genetic diseases utilizing its proprietary CRISPR-GNDM® epigenome editing technology, announced an update regarding the development timeline of its ongoing MDL-101.

The Company has been making steady progress toward achieving key milestones originally targeted for 2025. However, as a result of changing external contractors and delays in material supplies necessary for some studies, the project schedule is being adjusted. Importantly, this delay is not due to any technical issues, but rather to the time required for alignment with third-party partners.

As a result, the Company is now targeting 2026 for the achievement of major development milestones. We remain fully committed to the successful execution of this project and will continue to strengthen collaboration with all involved parties to ensure steady advancement. We will report the detailed timing of the IND filing as soon as it becomes available.

MDL-101 represents a critical component of our long-term growth strategy. While this timeline adjustment may have some near-term implications, it reflects our deliberate prioritization of quality and strategic alignment. We believe this decision will support greater long-term value creation. The Company will continue to provide timely and transparent updates as development progresses, and we sincerely appreciate the continued support of our shareholders and stakeholders.
The impact of this transaction on the consolidated financial results for the current fiscal year is expected to be minor.

About Modalis
Modaris Corporation (TSE: 4883), established in 2016, has a research and development base in Massachusetts, USA, and is a leading company in the development of therapeutic drugs using CRISPR-based epigenome editing technology. Based on our scalable platform technology, we develop therapeutics for patients suffering from serious genetic disorders such as muscle diseases, CNS diseases and cardiomyopathies. For more information, please visit our website at (www.modalistx.com/jp/)